Buy Voveran SR

Voveran SR

What is Voveran SR?

Voveran SR is a prescription-only medication marketed in Hong Kong for the management of moderate to severe pain and inflammatory conditions. Each tablet contains 100 mg of diclofenac in a sustained-release (SR) formulation, allowing a single daily dose. Diclofenac belongs to the non-steroidal anti-inflammatory drug (NSAID) class and acts as a pain-relief and anti-inflammatory agent. The product is regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance.

How Voveran SR Works in the Body

Diclofenac inhibits the cyclooxygenase (COX) enzymes - both COX-1 and COX-2 - which are required for the synthesis of prostaglandins. Prostaglandins mediate inflammation, pain, and fever. By reducing prostaglandin production, diclofenac decreases the sensitivity of nerve endings to pain signals and limits the inflammatory response. The sustained-release matrix gradually releases diclofenac over 24 hours, providing a more stable plasma concentration, which helps maintain pain control throughout the day.

Conditions Treated by Voveran SR

Voveran SR is approved in Hong Kong for the following indications:

• Osteoarthritis and rheumatoid arthritis pain
• Ankylosing spondylitis
• Acute musculoskeletal pain (e.g., sprains, strains)
• Post-operative pain after minor surgery
• Primary dysmenorrhea (menstrual pain)

These uses reflect the therapeutic role of diclofenac as an NSAID for pain and inflammation.

Off-Label and Investigational Applications

Diclofenac has been studied for off-label uses such as migraine relief and certain neuropathic pain syndromes. However, these indications are not approved by the Hong Kong regulatory agencies and should only be considered under close medical supervision, with a clear risk-benefit assessment.

Who Should Use Voveran SR? Contraindications

Absolute Contraindications

• Known hypersensitivity to diclofenac or any other NSAID
• Active or history of gastrointestinal ulceration or bleeding
• Severe congestive heart failure (NYHA class III-IV)
• End-stage renal disease requiring dialysis
• Third-trimester pregnancy (risk of premature closure of the fetal ductus arteriosus)

Relative Contraindications

• Mild to moderate renal impairment (dose adjustment may be required)
• Mild to moderate liver disease
• Elderly patients (higher risk of GI bleeding and renal effects)
• Concurrent use of anticoagulants, antiplatelet agents, or selective serotonin reuptake inhibitors (SSRIs)
• History of cardiovascular disease (ischemic heart disease, stroke)

Special Populations

• Pregnancy: Use only if the potential benefit outweighs the risk; avoid in the third trimester.
• Breastfeeding: Diclofenac is excreted in breast milk; consult a healthcare professional before use.
• Pediatrics: Not recommended for children under 18 years of age.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Upper abdominal discomfort or dyspepsia
• Mild headache
• Dizziness
• Skin rash or mild itching
• Mild elevation of liver enzymes (usually asymptomatic)

Serious Adverse Events

• Gastrointestinal bleeding, perforation, or ulcer (may be fatal)
• Increased risk of myocardial infarction or stroke, especially with long-term use
• Acute renal failure or worsening of existing kidney disease
• Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis
• Hepatotoxicity (hepatitis, jaundice)

Drug Interactions

• Anticoagulants (e.g., warfarin): Increased bleeding risk - monitor INR closely.
• Other NSAIDs or aspirin: Additive GI toxicity - avoid co-administration unless advised.
• SSRIs/SNRIs (e.g., sertraline, venlafaxine): Heightened bleeding risk.
• ACE inhibitors, ARBs, diuretics: Potential reduction in renal perfusion - monitor kidney function.
• Lithium: Diclofenac may increase serum lithium levels - check lithium concentrations.
• Methotrexate: Reduced clearance of methotrexate, raising toxicity risk.

Food and Lifestyle Interactions

• Take Voveran SR with food or a full glass of water to minimize gastric irritation.
• Limit alcohol consumption, as it can increase the risk of stomach bleeding.
• Caution when driving or operating machinery if you experience dizziness or visual disturbances.
• Avoid prolonged exposure to sunlight if you develop photosensitivity reactions.

Dosing and Administration Guidelines

• Standard dose: One 100 mg Voveran SR tablet taken orally once daily, preferably with food.
• Renal impairment: For moderate renal dysfunction (creatinine clearance 30-60 ml/min), consider a reduced dose of 50 mg once daily under physician guidance.
• Hepatic impairment: Use the lowest effective dose; monitor liver function tests regularly.
• Elderly patients: Start at the lowest effective dose (often 50 mg once daily) and titrate cautiously.
• Missed dose: If you miss a dose and it is within 12 hours of the scheduled time, take it immediately. Skip the missed dose if it is closer to the next scheduled dose; do not double-dose.
• Overdose: Symptoms may include severe stomach pain, nausea, vomiting, dizziness, or ringing in the ears. Seek emergency medical care; activated charcoal may be administered if ingestion is recent. No specific antidote exists.
• Discontinuation: No tapering is required for short-term use. For chronic therapy, gradual dose reduction can help minimize rebound pain.

Monitoring and Follow-Up

• Baseline labs: Liver function tests (ALT, AST), renal function (serum creatinine, eGFR), and complete blood count before initiating therapy.
• Follow-up labs: Every 3-6 months for patients on long-term therapy, or sooner if clinical signs suggest toxicity.
• Blood pressure monitoring: NSAIDs can cause fluid retention and raise blood pressure; check regularly in hypertensive patients.
• Gastrointestinal protection: Consider a proton-pump inhibitor for patients at high GI risk.

Storage and Handling

• Store Voveran SR tablets at room temperature (15-30 °C), away from excess moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets after the expiration date printed on the package.
• Unused medication should be disposed of according to local pharmaceutical waste guidelines or returned to a pharmacy for safe disposal.

Medication-Specific Glossary

Cyclooxygenase (COX)

An enzyme that converts arachidonic acid to prostaglandins, which mediate inflammation and pain.

Sustained-Release (SR)

A formulation that releases the active ingredient gradually over an extended period, allowing once-daily dosing.

Non-Steroidal Anti-Inflammatory Drug (NSAID)

A class of medications that reduce inflammation, pain, and fever by inhibiting COX enzymes.

Prostaglandins

Lipid compounds that promote inflammation, pain, and fever; reducing their synthesis alleviates these symptoms.

Gastrointestinal Bleeding

A serious adverse effect where the lining of the stomach or intestines is damaged, leading to internal bleeding.

Medical Disclaimer

This article provides educational information about Voveran SR and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.